/Regeneron%20Pharmaceuticals%2C%20Inc_%20logo%20on%20phone-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Tarrytown, New York-based Regeneron Pharmaceuticals, Inc. (REGN) discovers, invents, develops, manufactures, and commercializes medicines for treating various serious medical conditions. Valued at a market cap of $76.6 billion, the company’s portfolio boasts nine marketed drugs - Eylea, Dupixent, Praluent, Kevzara, Libtayo, Evkeeza, Inmazeb Arcalyst, and Zaltrap.
The biotech company's shares have lagged behind the broader market over the past 52 weeks. Regeneron has declined 26.5% over this time frame, while the broader S&P 500 Index ($SPX) has soared 20.7%. Moreover, the stock is down 1.7% on a YTD basis, compared to SPX’s 2.2% gain during the same time frame.
